1
VDPAM 445Swine Topics
Respiratory Disease Control
Dr. Alex RamirezVeterinary Diagnostic and
Production Animal MedicineIowa State University
2
General introduction
3
Endemic Pneumonia • App- continual outbreaks, chronic pleuropneumonia
– Sometimes other bacteria as well• Enzootic Pneumonia
– Mycoplasma hyopneumoniae– Pasteurella multocida
• Porcine Respiratory Disease Complex– All of the above (especially M. hyo)– PRRSV– SIV– Others: PCV2, PRV, H. parasuis, S. suis,
4
Diagnostics• Gross pathology: APP versus all others
– APP & A. suis vs. others• Organism identification
– Culture– FA– PCR– IHC: immunohistochemistry (with histopath)
• Fixed tissue, easy sample preservation
• Histopath– Prove disease, organism presence is insufficient
5
Question: Is this mycoplasma?
6
Diagnostics• Serology: serological profiling
– Timing of infection but not necessarily timing of disease
• Sampling issues– Tissue preservation in formalin
• Buffered• Multiple sites• <1cm tissue thickness
– Number of animals• Example on next slide
– Sick (necropsy) versus healthy (slaughter checks)
7
Diagnostic Sampling Strategies
• Small numbers of pigs will result in missed diagnosis– PRDC case: 21 pigs submitted for necropsy–Pathology/microbiology:
– No lesions =5 Gastric ulcer = 2– PMWS = 5 PRRSV = 2– SIV? = 1 APP? = 3 (non-typeable)– P. mult. = 2 Bordetella = 2– Strep suis = 1 M. hyo = 8
– Serology: M. hyo+, SIV+, PRRSV (late +)– Slaughter check: Low average percent pneumonia,
a few pigs severe
8
Diagnostic Considerations: Value of Tests
• Laboratory tests should fit with clinical observations– Pigs cough: Pursue rule-outs (M. hyo, influenza)– Pigs grow slowly without overt disease - diets/environment?
• Specific versus non-specific tests– Necropsy and slaughter exams (disease severity)– Laboratory tests (agent identification)– Record analysis (rarely identifies a specific cause)
• Documenting management activities– “Gum shoe” approach
• One revealing observation is often worth more than 100 serological tests
• SOP vs. Actual
9
Mycoplasma hyopneumoniae
10
Mycoplasma hyopneumoniae• Primary cause of enzootic pneumonia
– Most herds are infected except SPF herds
• Transmission is via aerosol– Air is PCR positive– Difficult to prevent between herd spread
• Disease often manifested in finishing– Organism very slow to grow (weeks)– A few get infected from sows spreads slowly through
nursery pigs– Lateral transmission from older pigs
11
Mycoplasma hyopneumoniae
• Diagnosis– Clinical signs: only cough 10 days after challenge
• Severe sickness with infection of SPF herds?• Mild - minimal consequence in otherwise
disease free pigs– Macroscopic lesions
• Anterior-ventral consolidation• Not specific to M. hyo
12
Mycoplasma hyopneumoniae
13
Mycoplasma hyopneumoniae• Diagnosis
– Histopathology: • peribronchiolar
lymphocytic cuffing– Organism ID
• FA- need fresh tissue, approx. 50% sensitivity
• Culture - slow grow, overgrowth by M. hyorhinis
• PCR - “It’s everywhere”• IHC
– Serology: several ELISA’s available• Vaccination will also induce titers that persist for
a short time
14
Mycoplasma Vaccination• Second most common vaccine used in growing pigs
– Common in population– Potentiator of other respiratory disease
• Issues– Mandatory (?) in herds with continuous flow, multiple rooms
within the same building, virulent PRRSV – One vs. two dose products
• Use one dose in “controlled” situations or if labor is a big concern
• Two doses will almost always be better• Start early (3weeks)• Product cost is usually equal• Many combine with PCV2 vaccination
15
Mycoplasma Vaccination• Maternal antibody interference
– Probably will not interfere with vaccine induced protection– No real reason to vaccinate sows pre-farrow
• Only vaccinate gilts before entering herd
• PRRS eradication Mycoplasma eradication– Consider where pigs will be grown and finished– May still need to vaccinate pigs
16
M. hyo Treatment plan• Antibiotics?
– Now– Earlier– Routes
• Water• Feed• Injectable
• Control other diseases• Vaccination
– Other groups– Timing – watch for PRRS seroconversion
17
Actinobacillus pleuropneumoniae(APP)
18
Actinobacillus pleuropneumoniae (APP)
• Cause of contagious pleuropneumonia• Transmission by close contact and short
distance aerosols• Many pigs harbor organism in upper airways
– Clinical disease occurs with environmental stress in many cases• Malfunctioning curtain controller temperature
fluctuation organism gains entrance to lung severe (bad), rapidly developing necrotizing and hemorrhagic pneumonia with pleuritis
19
Actinobacillus pleuropneumoniae (APP)
• Clinical signs–Sudden death–Sudden onset of rapid, deep breathing–Minimal cough (not an airway irritant)–Fever initially or if mild-to-moderate;
subnormal in severely affected pigs–Hemoptosis and blood from nostrils in agonal
phase (euthanize if possible)–Mortality can reach 10% of barn in one day–Pigs quit eating AND DRINKING
20
Actinobacillus pleuropneumoniae (APP)
• Post-mortem lesions–Necrotizing, hemorrhagic, usually multi-focal
pneumonia–Pleuritis will be present if pig survives for at
least 18 hours after challenge–Similar lesions can be seen with
Actinobacillus suis– If APP mass treatment via injection often
indicated; other types of pneumonia treated less aggressively; can’t wait for test results to start therapy
21
Actinobacillus pleuropneumoniae (APP)
22
Actinobacillus pleuropneumoniae (APP)
• Diagnosis– Initially: clinical signs and gross pathology– Culture: isolation followed by capsular serotyping
• Some relationship between capsular serotype and virulence: Type 1’s are worst; followed by 5’s
• USA: 1, 5, 7 and 3 are most common (odd numbers)• Europe: 2 and 6 are most common
– Serology• Complement fixation: recent infection• ELISA’s: capsule, endotoxin, cross-reactivity problems• Hemolysin neutralization: cross-reactions with A. suis
23
APP Vaccination• Most commercial vaccines are bacterins
– Administer 2X at 2-4 week interval prior to finishing – Capsular serotypes must be matched
• Use autogenous vaccines if:–Commercial vaccines don’t contain the
correct serotype–May have within serotype heterogeneity
– Marginally effective: lack ApX toxins which are the main virulence factors for causing disease
– Side effect potential:• Injection site reactions• Fever, off-feed, reduced daily gain
24
APP Vaccination• Newer vaccines
– Capsular deficient mutant (MLV): BINOBL• Given IM• Frozen product: order, shipped on dry ice,
use immediately• Limited replication at injection site• Sufficient production of ApX toxins to induce a
protective immune response–Riboflavin deficient mutant
• Not commercially available• Knock out riboflavin synthetase• Add riboflavin to organism and inject IM
25
APP Treatment Plan
• Antibiotics– YES!! ASAP
• INJECTABLE• Water• Feed
– Duration of treatment
• Ventilation• Vaccination ?• Different source of pigs
26
Actinobacillus suis
27
Actinobacillus suis• Will behave like APP but less severe and
short term• Problem with “healthier” herds• Generalized septicemia like H. parasuis,
erysipelas• Produces Type I hemolysin• No commercial vaccines available• Autogenous vaccines used in
refractory cases
28
A. suis Treatment Plan
• Antibiotics– APP vs A. suis need immediate action– Sources
• Injectable• Water• Feed ???
• Correct diagnosis is critical• Vaccination with autogenous??
29
Pasteurella multocida
30
Pasteurella multocida Pneumonia
• Not a primary cause of pneumonia– Experimental infection only with active M. hyo
infection present– “Fuzzy thinking”: not important because
secondary pathogen but primary causes are nearly always present!!• Medication of pigs with non-App pneumonia
is mostly directed at P. multocida–Acute swine influenza outbreaks–Enzootic pneumonia or PRDC–Environmental mishaps
31
Pasteurella multocida Pneumonia
• Little known about pathogenesis– Studies just beginning– Generally Type A, non-AR toxin producing– Normal inhabitant of upper airways
• Can cause pleuritis• Diagnosis
– Culture and sensitivity– Sort out primary causes
32
P. multocida Treatment Plan
• Antibiotics– Injectable– Water– Feed
• Environment – Ventilation• Address other diseases
– PRRS– Mycoplasma– Etc.
33
Atrophic Rhinitis(AR)
34
Atrophic Rhinitis• Bordetella bronchiseptica
– Causes atrophic rhinitis– Enables P. multocida to colonize nasal epithelium
• Pasteurella multocida– Causes progressive atrophic rhinitis– Produces AR toxin (dermatonecrotoxin)
• Highly potent: inject small quantity turbinate atrophy
– Mainly capsular Type D but also Type A
35
Atrophic Rhinitis• Clinical signs
– Deviated snout: side ways or pushed up– Tear staining at medial canthus– Sneezing– Bleeding from nostrils
• Lesions– Turbinate atrophy: primarily ventral scroll of
ventral turbinate– Septal deviation
36
Atrophic Rhinitis
37
Atrophic Rhinitis• Severity influenced by:
– Air quality and environment; especially in nurseries– Genetics
• Yorkshires more susceptible to developing severe lesions
–Age of sow herd: immunity of dams• Colostral antibody levels• Level of shedding vertical transmission• Age at infection
–Weaning age: <14 days eliminates vertical transmission
38
Atrophic Rhinitis• Stepwise approach
– Sow vaccination pre-farrowing• Gilts pre-breeding is always recommended
– LA200 (200 mg/ml oxytetracycline) to piglets• 15 mg/# dose• 1, 7, 14, 21 days or 1, 7-10, weaning
– Naxcel (2 mg/# dose) instead of LA200• No benefit against Bordetella bronchiseptica
– Vaccinate pigs• Two doses: 7 days and weaning• One dose: weaning
39
AR Treatment Plan
• Antibiotics– Water– Feed– Injectable
• Prevention– Antibiotics– Vaccination
• Environment
40
Psuedorabies(Aujesky’s or PRV)
41
Pseudorabies Virus• Eradicated from the USA commercial herds
in late 2003 to early 2004• Respiratory disease in any age pigs in
addition to CNS signs in neonates and reproductive disease in sows
• Occasional necrotic rhinitis crusty nose and nasal discharge
• Important rule-out (along with SIV and PRRS) for sow herd off-feed– Will have fever
42
PRV Vaccination• Vaccines were highly effective• Regulatory based vaccination in Stage II areas
– Vaccinated sow herd 4 times per year- IM– Vaccinated pigs once IM by 12 weeks of age
• In herds with active infections– Vaccinated pigs at birth intra-nasally
• Used vaccines that were approved for IN use, must replicate in the nasal epithelium to be effective
– Vaccinated pigs twice IM• Vaccine reduced shedding in individual pigs
– Can stop shedding on a population basis
43
PRV Eradication
• Blanket vaccination to reduce/eliminate shedding and transmission
• Improve internal biosecurity– AIAO production– People, equipment movement
• Improve external biosecurity– Hog truck sanitation
• Monitor closely via serology to determine where failure (active infection) is occurring
44
Other Viruses
45
Other Viruses• PRCV
– Mild respiratory disease in young pigs– Natural deletion mutant of TGE virus
• Can’t attach to intestinal epithelium– Significance ?????
• Test cross reacts with TGE
• Inclusion body rhinitis– Porcine cytomegalovirus– Common disease in early nursery pigs– High pitched sneezing– Minimal clinical impact if no other problems– Severely affected will develop necrotic rhinitis
46
Other bacteria
47
Other bacteria
• Will be discussed in other sections• Salmonella cholerasuis
– Interstitial pneumonia – Wet lung– Septicemia – purple pigs– +/- diarrhea
• Steptococcus suis– Cranioventral consolidation
• Haemophilus parasuis
48
Agents Discussed in future
49
Swine Influenza(SIV)
50
Swine Influenza Virus (SIV)• Type A influenza virus• H1N1: traditional strain in US• H3N2: new strain in US 1998
– Present in Europe for many years– Some evidence for presence in US before– Spread throughout country in 2-3 years
• H1N2: Detected in Indiana 1999– Combination of H1N1 and H3N2
• Others: Exposure to water fowl outbreak limited to a one or a few herds
51
Swine Influenza Virus (SIV)
• Clinical signs– Short term disease: <4-7 days– Fever: variable– Respiratory signs: 1-2 days after challenge
• Increased rate• “Thumps”: abdominal breathing• “Wet Cough”: minimal with pure infection
• Gross lesions–Look like M. hyo
52
Answer: SIV
53
SIV Vaccination• Strains: H1N1 (traditional), H3N2 (new)• Sow herd vaccination: common, concerns?• Pig vaccination
– Two doses recommended, often one dose given– Relatively high cost – Multivalent vaccines and/or autogenous– Role of maternal antibody interference
• Vaccinate sows pre-farrowing protective titers until 12 weeks of age
• MDA’s may interfere until 8-10 weeks of age small time frame to vaccinate
– Original antigenic sin
54
Porcine Reproductive and Respiratory Syndrome Virus
(PRRS)
Discussed in another lecture
55
Circovirus(PCV2 & PCVAD)
See Dr. Baker’s Lecture
56
Porcine Circovirus Type II• Type I: cause of infectious congenital tremors?;
porcine cell line contaminant• Type II: Cause of PCVAD (Porcine Circovirus
Associated Disease); old name = PMWS (post-weaning multi-systemic wasting syndrome) – Depletion of germinal centers in lymph nodes and
Peyer’s patches are characteristic lesions• Much virus located in these tissues• Virus also present in normal pigs and tissues• Lesions like PRRS
– Disease in US: PRRS associated, mild, older pigs
– Disease in Europe: devastating, younger animals
57
PCV2
• Small DNA virus none-enveloped– Hard to disinfect
• Present in most pigs– Exposure is VERY common– Negative herds ???
• Concern with present case definition (PMWS/PCVAD)1. Wasting2. Lymphoid depletion3. PCV2
• Excellent web site www.pcv2.org
58
Vaccines
• Just on the market in 2006• In Europe have had a vaccine from Merial
but for sows only!• ISU involved in development of
one vaccine (chimeric with Fort Dodge)• Results?
– So far looking VERY PROMISSING!
59
PCV Vaccines
60
PCVAD is typically seen in the 10-20 week old pigs in the US
-Morbidity 2-25%-Mortality 1-10%
PCVAD is usually seen in 4-10 week old pigs in Canada and Europe
Courtesy Dr. J. Harding
61
Markedly enlarged inguinal lymph nodes
are commonly observed in pigs with
PCVAD
62
Porcine Dermatitis and Nephropathy Syndrome
(PDNS)
Etiology unknownPRRSPCV2PRRSV + PCV2P. multocidaStreptococcus sp.
63
PCV2 coinfections in 484 U.S. field cases: ISU-VDL
9
164
10
77
13 3
9268
3711
020406080
100120140160180
PCV2 Alon
e
PCV2+PRRSV
PCV2+PRRSV+SIV
PCV2+PRRSV +
M.h
yo.
PCV2+SIV
PCV2+SIV
+M
.hyo
.
PCV2+M
. hyo
.
PCV2+Bac
teria
l sep
ticem
ia
PCV2+Bac
teria
l pne
umon
ia
PCV2+ O
ther
s
Num
ber
of C
ases
Rarely see PCV2 singular infection
64
PCV2 Treatment Plan
• Vaccination– Earlier the better
• Work on co-infections!
65
Acknowledgements
• I would like to recognize others for their significant contributions to this presentation:– Dr. Brad Thacker– Dr. Locke Karriker– Dr. Pat Halbur
66
Questions ?
Top Related